Feasibility of advanced stereotactic radiotherapy for brain metastases
Isotoxic High Dose (iHD) Fractionated Stereotactic Radiation Therapy (fSRT) for Intact Brain Metastases : a Feasibility Study
NA · Ruijin Hospital · NCT06231186
This study is testing a new type of precise radiation treatment for patients with brain metastases to see if it can control tumors better and improve their quality of life compared to standard methods.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 35 (estimated) |
| Sex | All |
| Sponsor | Ruijin Hospital (other) |
| Drugs / interventions | radiation |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Trial ID | NCT06231186 on ClinicalTrials.gov |
What this trial studies
This study evaluates the feasibility of using advanced stereotactic radiotherapy (iHD-SRT) for patients with brain metastases. It focuses on patients with measurable lesions who can undergo this precise treatment, which aims to improve tumor control while minimizing cognitive side effects. The study is designed to assess the effectiveness of this approach compared to traditional methods, with a focus on patient survival and quality of life. The use of high-resolution technology allows for greater accuracy in targeting tumors, potentially leading to better outcomes.
Who should consider this trial
Good fit: Ideal candidates are adults with confirmed brain metastases who have a good performance status and measurable lesions suitable for stereotactic radiotherapy.
Not a fit: Patients with diffuse brain metastases or severe medical complications that contraindicate radiotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve survival rates and quality of life for patients with brain metastases.
How similar studies have performed: While there have been studies on stereotactic radiotherapy, this specific approach is novel and has not been extensively tested in a prospective randomized controlled setting.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Ability to understand and willingness to participate the research and sign the consent form * ECOG PS 0-2 * The primary or metastatic lesion was confirmed by pathological histology as a malignant tumor * Head MRI diagnosis of brain metastasis with measurable lesions and technically feasible SRT (no more than 15 in number and 20cc in volume) * Estimated survival time ≥ 3 months Exclusion Criteria: * Diffuse brain metastases, or combined with meningeal metastases, or technically difficult to perform SRT * With severe internal medicine complications or absolute contraindications for radiotherapy * other sufficient reasons to be unqualified, such as potential non-compliance with the clinical protocol, etc
Where this trial is running
Shanghai, Shanghai Municipality
- Ruijin Hospital — Shanghai, Shanghai Municipality, China (RECRUITING)
Study contacts
- Principal investigator: Jiayi Chen — Ruijin Hospital
- Study coordinator: Dan Ou, MD
- Email: od12341@rjh.com.cn
- Phone: 8618801970632
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Brain Metastases, Adult, Stereotactic Radiotherapy